Skip to search formSkip to main contentSkip to account menu

10 ML arsenic trioxide 1 MG/ML Injection [Trisenox]

Known as: Trisenox 10 MG in 10 ML Injection, Trisenox 10 MG per 10 ML Injection, 10 ML Trisenox 1 MG/ML Injection 
National Institutes of Health

Related topics

Related topics

8 relations
Hydrochloric AcidInjectionSodium HydroxideTrisenox

Broader (1)

arsenic trioxide Injection [Trisenox]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Cost-Effectiveness of Arsenic Trioxide + All-Trans Retinoic Acid Compared with All-Trans Retinoic Acid + Idarubicin in the Treatment of Newly Diagnosed Acute Promyelocytic Lymphoma LEUKEMIA in Canada
2007
2007
Arsenic metabolism in multiple myeloma and astrocytoma cells
Arsenic trioxide (As2O3, Trisenox®) is used to treat patients with refractory or relapsed acute promyelocytic leukemia (APL). Its… 
2005
2005
Antitrust Modernization Commission “ Antitrust and the New Economy ” November 8 , 2005
I am Senior Vice President and General Counsel of Cephalon, Inc., a leading biopharmaceutical company based in suburban… 
2004
2004
Arsenic Trioxide (Trisenox® ATO), Ascorbic Acid (AA) and Dexamethasone (Dex) Pulses (TAD) for Relapsed Refractory Progressive Multiple Myeloma (MM) Patients (pts); a Final Report.
ATO is a novel anticancer agent whose unique multifaceted mechanisms of action offer a scientific rationale for investigation in… 
2004
2004
Arsenic Trioxide (Trisenox®) with/without Thalidomide in Patients with Myelodysplastic Syndromes (MDS) Produces Hematologic Improvement (HI).
In a previous clinical trial, we have shown that 7/28 MDS patients, belonging to IPSS intermediate and high risk categories… 
2004
2004
Prolonged Administration of Arsenic Trioxide (Trisenox®) for Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) at MD Anderson Cancer Center: A Phase II Study.
The value of prolonged administration of arsenic trioxide (ATO) was examined in patients (pts) with MDS and CMML. ATO (0.25 mg/kg… 
2002
2002
Current Trends in the Treatment of Acute and Chronic Myelogenous Leukemia
Acute myelogenous and chronic myelogenous leukemia are uniformly fatal if left untreated. Treatment with conventional… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)